Phase I/II Trial and Pharmacokinetic Study of Cixutumumab in Pediatric Patients With Refractory Solid Tumors and Ewing Sarcoma: A Report From the Children's Oncology Group

PURPOSE: A phase I/II study of cixutumumab (IMC-A12) in children with refractory solid tumors was conducted. This study was designed to assess the toxicities, pharmacokinetics, and pharmacodynamics of cixutumumab in children to determine a recommended phase II dose and to assess antitumor activity i...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Principais autores: Malempati, Suman, Weigel, Brenda, Ingle, Ashish M., Ahern, Charlotte H., Carroll, Julie M., Roberts, Charles T., Reid, Joel M., Schmechel, Stephen, Voss, Stephan D., Cho, Steven Y., Chen, Helen X., Krailo, Mark D., Adamson, Peter C., Blaney, Susan M.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2012
Assuntos:
Original Reports
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3269952/
https://ncbi.nlm.nih.gov/pubmed/22184397
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2011.37.4355
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados